Sun Pharma Advanced Research Company Limited (BOM:532872)
India · Delayed Price · Currency is INR 196.80
-2.65 (-1.33%)
At close: Aug 21, 2026
Sun Pharma Advanced Research Company Company Description
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally.
It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications.
The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
Sun Pharma Advanced Research Company Limited
| Country | India |
| Founded | 2006 |
| Industry | Pharmaceutical Preparations |
| Employees | 279 |
| CEO | Anilkumar Raghavan |
Contact Details
Address: 17/B, Mahal Industrial Estate Mumbai, 400093 India | |
| Phone | 91 22 6645 5645 |
| Website | sparc.life |
Stock Details
| Ticker Symbol | 532872 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anilkumar Raghavan | Chief Executive Officer |
| Anup Rathi | Chief Financial Officer |
| Narendra Lakkad | Chief Operating Officer |
| Jaydeep Issrani | Head of Investor Relations |